medigraphic.com
Órgano Oficial del Instituto Nacional de Pediatría

2024, Number 5

<< Back Next >>

Acta Pediatr Mex 2024; 45 (5)

Pediatric fatal case of Rickettsia rickettsii and SARS-CoV-2 coinfection

Rosas SD, Félix RMF, Rivera RCN, Calleja LT, Álvarez MJB, Álvarez HG

Language: Spanish
References: 38
Page: 458-465
PDF size: 337.46 Kb.


ABSTRACT

Background: Rocky Mountain spotted fever (RMSF) presents with non-specific clinical manifestations that may be mistaken for other febrile illnesses, including COVID-19. Coinfection by SARS-CoV-2 with other pathogens has been previously reported, however, not between this virus and R. rickettsii. We hereby present a fatal case in a child hospitalized in an endemic RMSF region.
Clinical case: An 11-year-old male patient presented with a 7-day history of exanthematous fever accompanied by neurological deterioration and respiratory distress. Acute SARS-CoV-2 infection was confirmed through antigen testing and polymerase chain reaction (PCR) on a respiratory sample. The patient had documented tick exposure, raising simultaneous suspicion of RMSF. Blood samples and pathology revealed R. rickettsii infection. Rapid systemic deterioration, unresponsive to implemented management, led to death within five hours of admission.
Conclusions: This fatal case demonstrated acute coinfection by R. rickettsii and the SARS-CoV-2 virus, likely contributing to complications and expediting the fatal outcome. Medical personnel should contemplate the presence of coinfections involving both pathogens, particularly in endemic regions of the country.


REFERENCES

  1. Eremeeva ME, Zambrano ML, Anaya L, Beati L, Karpathy SE,Santos-Silva MM, et al. Rickettsia rickettsii in Rhipicephalusticks, Mexicali, Mexico. J Med Entomol. 2011;48(2):418-21.

  2. Biggs HM, Behravesh CB, Bradley KK, Dahlgren FS, DrexlerNA, Dumler JS, et al. Diagnosis and management of tickbornerickettsial diseases: Rocky Mountain spotted feverand other spotted fever group rickettsioses, Ehrlichioses,and Anaplasmosis - United States. MMWR Recomm Rep.2016 May 13;65(2):1-44.

  3. de Oliveira SV, Willemann MCA, Gazeta GS, AngeramiRN, Gurgel-Gonçalves R. Predictive factors for fatal tick-borne spotted fever in Brazil. Zoonoses Public Health2017;64(7):e44-e50.

  4. Labruna MB, Mattar V S. Rickettsioses in Latin America,Caribbean, Spain and Portugal. Rev MVZ Córdoba 2011;16: 2435–57. doi:10.21897/rmvz.282

  5. Álvarez-Hernández G, Roldán JFG, Milan NSH, Lash RR,Behravesh CB, Paddock CD. Rocky Mountain spotted feverin Mexico: past, present, and future. Lancet Infect Dis2017;17(6):e189-e196.

  6. Gobierno de México. Dirección General de Epidemiología.Histórico Boletín Epidemiológico [Internet]. Secretaria deSalud; [Consultado: 2023 Aug 7]. Disponible en: https://www.gob.mx/salud/acciones-y-programas/historicoboletin-epidemiologico

  7. Álvarez-López DI, Ochoa-Mora E, Nichols Heitman K, BinderAM, Álvarez-Hernández G, Armstrong PA. Epidemiologyand clinical features of Rocky Mountain spotted fever fromenhanced surveillance, Sonora, Mexico: 2015-2018. Am JTrop Med Hyg 2021;104(1):190-7.

  8. Rodríguez-Muñoz L, Barrera-Salinas R, Sánchez-García C,Solórzano-Santos F, Vaquera-Aparicio DN, López-CastilloD. Spotted fever rickettsioses. Study of cases reported in asecondary care pediatric hospital of northeastern Mexico,2012-2022. Gac Med Mex. Doi:10.24875/GMM.22000354

  9. Galanakis E, Bitsori M. When to think of rickettsia. PediatrInfect Dis J. 2019;38(6S Suppl 1):S20-S23.

  10. Razzaq S, Schutze GE. Rocky Mountain spotted fever: aphysician’s challenge. Pediatr Rev 2005;26(4):125-30.

  11. Dean A, Asaithambi R, Neubauer HC. Murine typhus in 5children hospitalized for multisystem inflammatory syndromein children. Hosp Pediatr 2021;11(4):e61-e65. doi:10.1542/hpeds.2020-005652.

  12. Barbina S, Quiroga M, Petz C. An unsuspected caseof Rocky Mountain spotted fever: a lesson to keep abroad differential. J Investig Med High Impact Case Rep2022;10:23247096221145014.

  13. Consejo Nacional de Ciencia y Tecnología. COVID-19Tablero México [Internet]. [Consultado: 2023 Jun 27].Disponible en: https://datos.covid-19.conacyt.mx/

  14. Raczniak GA, Kato C, Chung IH, Austin A, McQuiston JH,Weis E, et al. Case report: co-infection of Rickettsia rickettsiiand Streptococcus pyogenes: is fatal Rocky Mountainspotted fever underdiagnosed. Am J Trop Med Hyg2014;91(6):1154-5.

  15. Licona-Enríquez JD, Delgado-de la Mora J, Álvarez-Hernández G. Caso fatal de coinfectada de rickettsiosis yvirus del dengue en México. Rev Med Inst Mex Seguro Soc2018;56(3):320-322.

  16. Greenmyer JR, Wyatt KD, Milanovich S, Kohorst MA, FerdjallahA. COVID-19-associated secondary hemophagocyticlymphohistiocytosis requiring hematopoietic cell transplant.eJ Haem 2022;3(3):1025-8. Doi:10.1002/jha2.456

  17. Chacón-Cruz E, Lopatynsky EZ, Machado-Contreras JR,Gatica-Herrera R, Zazueta OE. Fatal pediatric meningococcalinvasive disease caused by Neisseria meningitidisserogroup C and co-infected with SARS-CoV-2: Report ofa case in Tijuana, Mexico. Cureus 2022;14(2):e22100. doi:10.7759/cureus.22100

  18. WHO. Statement on the fifteenth meeting of the IHR(2005) Emergency Committee on the COVID-19 pandemic[Internet]. World Health Organization; [cited 2023Jun 27]. Available from: https://www.who.int/news/item/05-05-2023-statement-on-the-fifteenth-meeting-ofthe-international-health-regulations-(2005)-emergencycommittee-regarding-the-coronavirus-disease-(covid-19)-pandemic

  19. Zazueta OE, Armstrong PA, Márquez-Elguea A, HernándezMilán NS, Peterson AE, Ovalle-Marroquín DF, et al. RockyMountain spotted fever in a large metropolitan center,Mexico-United States border, 2009-2019. Emerg Infect Dis

  20. 2021;27(6):1567-76.20. Sahni A, Fang R, Sahni SK, Walker DH. Pathogenesis ofrickettsial diseases: Pathogenic and immune mechanismsof an endotheliotropic Infection. Annu Rev Pathol2019;14:127-52.

  21. de Andrade SA, de Souza DA, Torres AL, et al. Pathophysiologyof COVID-19: Critical role of hemostasis.Front Cell Infect Microbiol 2022;12:896972. doi:10.3389/fcimb.2022.896972

  22. Mittal A, Elias ML, Schwartz RA, Kapila R. Recognition andtreatment of devastating vasculopathic systemic disorders:Coronavirus disease 2019 and rickettsioses. Dermatol Ther2021;34(4). doi:10.1111/dth.14984

  23. Lamers MM, Haagmans BL. SARS-CoV-2 pathogenesis. NatRev Microbiol 2022;20(5):270-284. doi:10.1038/s41579-022-00713-0

  24. Toledo-Salinas C, Castaño-Jaramillo LM, Gutiérrez-AlonsoA, Scheffler-Mendoza SC. Síndrome multiinflamatoriosistémico pediátrico (MIS-C/PIMS): bases inmunológicasque sustentan el tratamiento. Act Pediatr Mex 2023; 4 (2):146-60. https://doi.org/10.18233/apm.v442i.2326

  25. Mansueto P, Vitale G, Di Lorenzo G, Arcoleo F, Mansueto S,Cillari E. Immunology of human rickettsial diseases. J BiolReg Homeost Agents 2008; 22 (2); 131-9.

  26. Holmes Z, Courtney A, Lincoln M, Weller R. Rash morphologyas a predictor of COVID-19 severity: A systematicreview of the cutaneous manifestations of COVID-19. SkinHealth Dis. 2022;2(3):e120.

  27. Buckingham SC, Marshall GS, Schutze GE, Woods CR, JacksonMA, Patterson LE, et al. Clinical and laboratory features,hospital course, and outcome of Rocky Mountain spottedfever in children. J Pediatr. 2007;150(2):180-4, 184.e1.

  28. Alvarez-Hernandez G, Murillo-Benitez C, Candia-Plata MdelC, Moro M. Clinical profile and predictors of fatal RockyMountain spotted fever in children from Sonora, Mexico.Pediatr Infect Dis J. 2015;34(2):125-30.

  29. Paddock CD, Alvarez-Hernandez G. Rickettsia rickettsii(Rocky Mountain spotted fever). Long SS, Prober CG,Fischer M. Principles and practice of pediatric infectiousdiseases. 5a ed. Elsevier; 2017. p. 971-976.

  30. Traeger MS, Regan JJ, Humpherys D, Mahoney DL, MartinezM, Emerson GL, et al. Rocky Mountain spotted fevercharacterization and comparison to similar illnesses in ahighly endemic area-Arizona, 2002-2011. Clin Infect Dis2015;60(11):1650-8. doi:10.1093/cid/civ115

  31. Yasuhara J, Kuno T, Takagi H, Sumitomo N. Clinical characteristicsof COVID‐19 in children: A systematic review.Pediatr Pulmonol. 2020;55(10):2565-75.

  32. Jay R, Armstrong PA. Clinical characteristics of Rocky Mountainspotted fever in the United States: A literature review.J Vector Borne Dis. 2020;57(2):114-20.

  33. Howard-Jones AR, Burgner DP, Crawford NW, Goeman E,Gray PE, Hsu P, et al. COVID-19 in children. II: Pathogenesis,disease spectrum and management. J Paediatr ChildHealth. 2022;58(1):46-53

  34. Han MS, Choi EH, Chang SH, et al. Clinical characteristicsand viral RNA detection in children with CoronavirusDisease 2019 in the Republic of Korea. JAMAPediatr. 2021;175(1):73–80. doi:10.1001/jamapediatrics.2020.3988

  35. Bal AK, Kairys SW. Kawasaki disease following RockyMountain spotted fever: a case report. J Med Case Rep2009;3:7320. doi:10.4076/1752-1947-3-7320

  36. Sun LR, Huisman TA, Yeshokumar AK, Johnston MV. Ongoingcerebral vasculitis during treatment of Rocky Mountainspotted fever. Pediatr Neurol 2015;53(5):434-438.doi:10.1016/j.pediatrneurol.2015.07.003

  37. Allen HC, Welliver RC Sr, Fogarty MW, Gessouroun M,Henry ED. Intravenous immunoglobulin therapy forcerebral vasculitis associated with Rocky Mountain spottedfever. J Pediatr Intensive Care 2017;6(2):142-144.doi:10.1055/s-0036-1587327

  38. Son MBF, Murray N, Friedman K, Young CC, Newham MM,Feldstein LR, et al. Multisystem inflammatory syndromein children - Initial therapy and outcomes. N Engl J Med2021;385(1):23-34.




2020     |     www.medigraphic.com